Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies
Arsanis Announces First Patient Dosed in Global Phase 2 Study of ASN100 for Prevention of Staphylococcus aureus Pneumonia
Arsanis Receives FDA Fast Track Designation for ASN100 for the Prevention of Staphylococcus aureus Pneumonia
Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ASN100 for the prevention of Staphylococcus aureus pneumonia in mechanically ventilated patients who are at high risk for S. aureus pneumonia.
Arsanis to Present Data at IDWeek 2016 Demonstrating Lack of Effectiveness of Standard Antibiotics on Progression to Staphylococcus aureus Pneumonia in Hospitalized, High-Risk Patients
Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Multidrug-Resistant Escherichia coli and Klebsiella pneumoniae using Monoclonal Antibody Technology